8-K
filed January 31, 2024, 6:59 PM ET
ticker TEVA
CIK 0000818686
earnings
confidence high
sentiment neutral
materiality 0.70
Teva FY2023 revenue $15.8B, Non-GAAP EPS $2.56; AUSTEDO $1.2B; 2024 guidance issued; revises prior results
TEVA PHARMACEUTICAL INDUSTRIES LTD
2023-FY EPS reported
-$0.50
revenue$15,846,000,000
- Full-year 2023 revenues $15,846M, up 7% in local currency; Q4 revenues $4,465M.
- Non-GAAP diluted EPS $2.56 (vs $2.52 in 2022); GAAP net loss $(0.50) per share.
- AUSTEDO annual revenue exceeded $1.2B (+28%); AJOVY $435M (+16%).
- 2024 outlook: revenue $15.7-$16.3B, Non-GAAP EPS $2.20-$2.50, free cash flow $1.7-$2.0B.
- Revision: $132M contingent consideration understatement; material weakness in internal controls identified.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
TEVA PHARMACEUTICAL INDUSTRIES LTD reported 2024 results: revenue $15.7 - $16.3 billion, EPS $2.20 - $2.50. Guidance initiated.
- Period
- 2024
- Revenue
- $15.7 - $16.3 billion
- EPS
- $2.20 - $2.50
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
2024 Business Outlook : Revenues of $15.7 - $16.3 billion Non-GAAP operating income of $4.0-$4.5 billion Adjusted EBITDA of $4.5 - $5.0 billion Non-GAAP diluted EPS of $2.20 - $2.50 Free cash flow of $1.7 - $2.0 billion
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended December 31, 2023 results: revenue $4.5 billion, EPS $0.41. Guidance initiated.
- Period
- the quarter ended December 31, 2023
- Revenue
- $4.5 billion
- EPS
- $0.41
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Q4 2023 FY 2023 Revenues $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share $0.41 $(0.50) Non-GAAP diluted EPS $1.00 $2.56
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the fiscal year ended December 31, 2023 results: revenue $15.8 billion, EPS $(0.50). Guidance initiated.
- Period
- the fiscal year ended December 31, 2023
- Revenue
- $15.8 billion
- EPS
- $(0.50)
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Q4 2023 FY 2023 Revenues $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share $0.41 $(0.50) Non-GAAP diluted EPS $1.00 $2.56
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.